High-Grade Glioma Market Size to Reach a CAGR of 3.45% during 2024-2034, Impelled by Advancements in Early Detection

High-Grade Glioma Market Outlook 2024-2034:

The high-grade glioma market size is expected to exhibit a CAGR of 3.45% during 2024-2034. The market is driven by the growing use of stereotactic radiosurgery to treat recurrent medical disorders because of its many related advantages, including targeted delivery, non-invasiveness, and shorter treatment times. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the High-Grade Glioma Market 

Advances in early detection and diagnostic technologies are significantly driving growth in the high-grade glioma market, offering new hope in the management of this aggressive and often fatal brain cancer. Recent technological innovations have transformed the diagnostic landscape, enabling clinicians to detect and characterize these tumors more effectively. One of the most impactful advances is in imaging technologies. Magnetic resonance imaging (MRI), particularly with enhancements like functional MRI (fMRI) and diffusion tensor imaging (DTI), provides detailed insights into tumor location, size, and its effects on surrounding brain structures. Additionally, positron emission tomography (PET) scans, combined with advanced tracers, can detect metabolic activity within tumors, offering valuable information on tumor aggressiveness and helping distinguish between high-grade gliomas and other brain lesions. Liquid biopsy is another groundbreaking development. By analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood or cerebrospinal fluid, liquid biopsies offer a non-invasive approach to early diagnosis and monitoring of high-grade gliomas. These tests can provide real-time insights into tumor genetics, enabling personalized treatment strategies and tracking tumor response to therapy. Moreover, artificial intelligence (AI) and machine learning algorithms are enhancing the accuracy of glioma detection and classification. These tools can analyze large datasets from imaging and molecular diagnostics to identify patterns that may not be apparent to human observers, facilitating earlier and more precise diagnoses. These technological advancements not only improve the chances of early intervention but also drive the high-grade glioma market by increasing demand for cutting-edge diagnostic tools. This, in turn, supports the development of targeted therapies and personalized treatment approaches, ultimately improving survival rates and quality of life for patients.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is a key driver of growth in the high-grade glioma market, addressing the urgent need for more effective interventions against these aggressive brain tumors. One of the most promising areas of advancement is in targeted therapies. These treatments, including inhibitors of specific molecular pathways such as EGFR and PI3K/AKT/mTOR, aim to disrupt tumor growth by targeting genetic mutations or signaling pathways unique to high-grade gliomas. Additionally, immunotherapy is gaining traction, with checkpoint inhibitors like pembrolizumab being explored for their potential to enhance the immune system’s ability to recognize and attack glioma cells. Gene and cell-based therapies also represent transformative innovations. Gene therapy approaches, such as oncolytic viruses that selectively infect and destroy tumor cells, offer a novel mechanism of action. Similarly, CAR-T cell therapy, which involves engineering a patient’s T-cells to target tumor-specific antigens, is under investigation for its potential to provide durable responses in glioma patients. Another area of focus is the development of combination therapies that integrate traditional treatments with novel agents to enhance efficacy and overcome resistance. For example, combining radiation therapy with DNA damage response (DDR) inhibitors can amplify tumor sensitivity to radiation, improving outcomes. These advancements are reshaping the high-grade glioma treatment landscape, driving market growth by expanding therapeutic options and offering new hope for improved survival. As these novel therapies progress through clinical trials and regulatory approval, they are expected to significantly impact patient care and market dynamics.

Marketed Therapies in High-Grade Glioma Market

Gliadel wafer (Carmustine polifeprosan 20 wafer): Arbor Pharmaceuticals/ Eisai 

Gliadel wafer (Carmustine polifeprosan 20 wafer) is recommended for the treatment of patients with newly diagnosed high-grade gliomas as an adjuvant to surgery and radiation. The activity of the Gliadel wafer is attributed to the release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, into the tumor resection cavity. When exposed to the watery environment of the resection cavity, the copolymer's anhydride linkages are hydrolyzed, releasing carmustine, carboxyphenoxypropane, and sebacic acid into the surrounding brain tissues.

Avastin (Bevacizumab): Genentech/Roche

Avastin (Bevacizumab), a monoclonal anti-vascular endothelial growth factor antibody, is used in combination with antineoplastic medicines to treat high-grade gliomas. Avastin is intended to inhibit VEGF, which may prevent the formation of new blood vessels, both normal blood vessels and those that feed tumors.

Temodar (Temozolomide): Merck & Co

Temozolomide is an oral alkylation agent. The postulated mechanism of action is based on the metabolites' ability to deposit methyl groups on DNA guanine nucleotides. The prodrug temozolomide is easily absorbed in the small intestine after oral treatment, and its tiny size (194 Da) allows for efficient blood-brain barrier penetration. It subsequently undergoes spontaneous intracellular hydrolysis, resulting in the formation of MTIC, a strong methylating agent. MTIC methylates several nucleobases, the most important being the guanine base. This causes nicks in the DNA, followed by apoptosis because cellular repair processes are unable to respond to the methylation nucleotide.

Emerging Therapies in High-Grade Glioma Market

BMX-001: BioMimetix 

BMX-001 is a metalloporphyrin, a unique type of redox-active small molecule. The active center is intended to resemble the center of superoxide dismutase. The main mechanism of action is the regulation of cellular signaling pathways. BMX-001 suppresses both NFkB and HIF-1a. By blocking these pro-survival and pro-angiogenic transcription factors, BMX-001 enhances radiation therapy tumor death while also decreasing tumor regrowth. Inhibiting NFkB limits critical components of the inflammatory cascade, hence protecting normal tissue from radiation-induced harm.

ONC201: Chimerix

ONC201, also known as dordaviprone, is a first-in-class small molecule imipridone that specifically binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP. ONC201 utilized orally appears to be well tolerated and effective in certain people with advanced cancer.

LAM561: Laminar Pharmaceuticals

LAM561 (2-hydroxyoleic acid (2-OHOA); idroxioleic acid, sodium) is a synthetic oleic acid derivative and the most advanced R&D oral product. This medicine affects the makeup of the plasma membrane in cancer cells, inhibiting the action of membrane-associated signaling proteins known to promote tumor growth and impact brain tumors. LAM561 is approaching the end of its clinical development phase and has demonstrated encouraging preliminary clinical activity in the treatment of aggressive brain cancers, specifically glioblastoma.

OS2966: OncoSynergy  

OS2966 is a humanized integrin β1 (CD29) blocking antibody being investigated for the treatment of glioblastoma. It inhibits the CD29/β1 integrin receptor, which is overexpressed in glioblastoma. This receptor regulates biological processes that let cancer cells grow, spread, and develop resistance to treatment. OS2966 is delivered to the brain by a process known as convection-enhanced delivery.

PTC596: PTC Therapeutic

PTC596 is a small-molecule tubulin-binding drug used for the treatment of high-grade glioma. The medication inhibits microtubule polymerization, resulting in cell cycle arrest. This reduces BMI1 protein levels and function while inducing G2-M mitotic arrest and apoptosis. PTC596 can be taken orally in the form of a suspension.

Detailed list of emerging therapies in High-Grade Glioma is provided in the final report.

Leading Companies in the High-Grade Glioma Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global high-grade glioma market, several leading companies are at the forefront of developing integrated platforms to enhance the management of high-grade glioma. Some of the major players include Merck & Co., Arbor Pharmaceuticals, and Eisai. These companies are driving innovation in the high-grade glioma market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

​In September 2023, the FDA granted new and updated indications for temozolomide (Temodar; Merck) capsules and injection, an alkylating medication, including adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma and treatment of adults with refractory anaplastic astrocytoma. The previously approved indication for treating adults with newly diagnosed glioblastoma with radiation followed by maintenance treatment remains unchanged.

Key Players in High-Grade Glioma Market:

The key players in the High-Grade Glioma market who are in different phases of developing different therapies are Arbor Pharmaceuticals, Eisai, Genentech, Roche, Merck & Co, BioMimetix, Chimerix, Laminar Pharmaceuticals, OncoSynergy, PTC Therapeutic, and Others.

Regional Analysis:

The major markets for high-grade glioma include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for high-grade glioma while also representing the biggest market for its treatment. This can be attributed to the rising incidence of the disease, advancements in medical technologies, and increased investment in R&D.

Moreover, the advancement in diagnostic tools, such as MRI, fMRI, and PET, which allow for earlier detection and precise tumor characterization, enabling more effective treatment planning, is driving the market growth.

Besides this, U.S.-based clinical trials are exploring novel approaches, such as CAR-T cell therapy and oncolytic viruses, which hold promise for improved outcomes. Regulatory incentives from the FDA, like orphan drug status and priority review, encourage the development of these cutting-edge treatments.

Recent Developments in High-Grade Glioma Market:

• In June 2024, Laminar Pharmaceuticals S.A. announced that patient recruitment for the CLINGLIO (NCT04250922) research had been completed after 140 adult patients were successfully enrolled. The CLINGLIO project is a phase 2b/3, randomized, placebo-controlled, multinational, double-blind clinical trial that compares idroxioleic acid to the standard of care (combined tumor excision and chemoradiotherapy) for the treatment of newly diagnosed glioblastoma patients.
• In November 2023, BioMimetix reported the results of its Phase II (NCT02655601) study, which is investigating BMX-001 in high-grade glioma patients. The findings revealed that BMX-001 when paired with radiation and temozolomide, improved median survival in glioma patients by 6.6 months. The candidate also reduced radiation-induced cognitive impairment and improved white matter integrity.
• In August 2023, Chimerix disclosed that ONC201 showed strong efficacy results in two early-stage clinical trials of 71 pediatric patients with H3K27M-mutant diffuse midline gliomas.
   

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the high-grade glioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the high-grade glioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current high-grade glioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800